HASTINGS PAUL J — SEC Form 4 filings
SEC reporting owner CIK 1309702. 15 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-01-08 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 7 filings — 59,337 shares, $219,802 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 9,697 shares @ $8.74 ($84,752) in Nkarta, Inc., filed 2024-01-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Nkarta, Inc. (NKTX) | Chief Executive Officer, Director | 11 | — | 6 legs · 58,457 sh · $194,828 | 9 |
| Pacira BioSciences, Inc. (PCRX) | Director | 1 | — | 1 leg · 880 sh · $24,974 | 2 |
| enGene Therapeutics Inc. (ENGN) | Director | 3 | — | — | 3 |
Form 4 filings — HASTINGS PAUL J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 1,776 @ $2.71 | EDGAR |
| 2026-06-17 | 4 | enGene Therapeutics Inc. (ENGN) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 26,046 @ $2.07 | EDGAR |
| 2026-01-08 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 94,000 @ $0 · Grant/award (A): 562,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 1,790 @ $1.79 | EDGAR |
| 2025-06-16 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 377,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 17,378 @ $2.20 | EDGAR |
| 2025-01-07 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 94,500 @ $0 · Grant/award (A): 565,500 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 1,770 @ $5.60 | EDGAR |
| 2024-06-18 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 5,230 @ $0 · Sale (S): 880 @ $28.38 · Grant/award (A): 12,179 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Nkarta, Inc. (NKTX) | Disposition to issuer (D): 12,358 @ $13 · Disposition to issuer (D): 137,642 @ $13.33 | EDGAR |
| 2024-01-18 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 9,697 @ $8.74 | EDGAR |
| 2024-01-08 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 85,000 @ $0 · Grant/award (A): 509,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-04 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1309702 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →